Skip to main content
OpenTrials
Completed

NCT Number: NCT01191931

Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)

Study design:

-The study will be a phase I like study to assess the extent to which prostate HistoScanning (PHS, the index test) can identify and characterize foci of prostate cancer when compared to histological samples harvested during radical prostatectomy (the reference test). The study will comprise 3 steps: first, defining the most suitable method for matching the TRUS (TransRectalUltrasonography) to histology (step 1); second, refining the algorithms (training set); third, verification of the PHS performances (test set).

Study objectives:

* Primary Objective:

* To evaluate the extent to which PHS can discriminate between malignant lesions of the prostate versus non-malignant tissue in 3D RF TRUS data using radical prostatectomy histological step sectioning as the reference test. * Secondary Objectives:

* To adapt and refine PHS tissue characterisation algorithms using RF data that were previously developed using grey-level data as input. * To assess the accuracy of PHS in predicting the volume of prostate cancers determined by histology. * To assess the ability of PHS to rule in or rule out the presence of cancer > or = 0.5 cc and of > or = 0.2 cc as determined by histology. * To evaluate the ability to discriminate primary Gleason pattern 4 and 5 versus 3 or less in tumours > or = 0.5 cc and > or = 0.2 cc. * To assess the ability of PHS to correctly risk stratify patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Bordet Institute, Brussels, Brussels Capital, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: >or=18 year-old
  • Histologically (positive biopsy) proven prostate cancer with primary and secondary Gleason patterns attributed.
  • Patient planned to undergo radical prostatectomy
  • Prostate cancer is deemed to be organ confined (T1-T2, Nx or No, Mx or Mo)
  • No prior treatment for prostate cancer, including any type of hormonal therapy
  • No major calcification is noted during the TRUS (i.e. (Diameter >or=5 mm, spread all over the prostate or blocking to much of the ultrasound signal).
  • Patient willing to give written informed consent

Exclusion criteria

  • Patients who are either unsuitable or unwilling to enter the study or to proceed to surgical investigation.

Sponsors and collaborators

Lead sponsor

Advanced Medical Diagnostics s.a.

Industry

Registry information

Acronym: PHS-02

Important dates

Study start
2008
Study completion
2012
First posted
Aug 31, 2010
Registry last updated
Oct 29, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.